Disease · MONDO_0009348
Trials143
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 143
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | Phase 3 | 1,334 | 2018-11-27 | Hodgkin Lymphoma | BLEOMYCIN, BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE | Its record names the disease | ClinicalTrials.gov |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | Phase 3 | 994 | 2025-06-12 | Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma | BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN HYDROCHLORIDE, NIVOLUMAB, VINBLASTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | Phase 3 | 600 | 2023-05-31 | Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma | BLEOMYCIN SULFATE, BRENTUXIMAB VEDOTIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, METHYLPREDNISOLONE, PREDNISONE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02181738 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | Phase 2 | 294 | 2018-12-11 | Hodgkin Disease | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | Phase 2 | 255 | 2023-12-21 | Hodgkin Lymphoma | BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN, NIVOLUMAB, VINBLASTINE | Its record names the disease | ClinicalTrials.gov |
| NCT02453594 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | Phase 2 | 211 | 2024-10-29 | Hodgkin Lymphoma | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | Phase 2 | 146 | 2024-10-16 | Classical Hodgkin Lymphoma | BLEOMYCIN, CYCLOPHOSPHAMIDE, DACARBAZINE, DOXORUBICIN, ETOPOSIDE, PEMBROLIZUMAB, PREDNISONE, PROCARBAZINE, VINBLASTINE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00742027 | Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | Phase 2 | 129 | 2021-06-03 | Classical Hodgkin's Lymphoma | PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03114683 | Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | Phase 2 | 96 | 2020-12-07 | Relapsed/Refractory Classical Hodgkin's Lymphoma | SINTILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03446040 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | Phase 1/2 | 92 | 2025-09-18 | Advanced Cancer | BMS-986258, HYALURONIDASE (HUMAN RECOMBINANT), NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00504504 | Rituximab and ABVD for Hodgkin's Patients | Phase 2 | 85 | 2013-07-09 | Lymphoma | BLEOMYCIN, DACARBAZINE, DOXORUBICIN, RITUXIMAB, VINBLASTINE | Its record names the disease | ClinicalTrials.gov |
| NCT02362997 | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | Phase 2 | 82 | 2022-12-08 | Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Phase 1 | 79 | 2025-09-23 | Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03155425 | PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma | Phase 2 | 75 | 2024-02-01 | Hodgkin Lymphoma, Adult | CAMRELIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02927769 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment | Phase 2 | 72 | 2025-02-10 | Hodgkin Disease | BENDAMUSTINE, BRENTUXIMAB VEDOTIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03209973 | A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma | Phase 2 | 70 | 2020-10-12 | Classical Hodgkin Lymphoma | TISLELIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04875195 | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | Phase 2 | 66 | 2025-02-10 | Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03397706 | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies | Phase 1/2 | 64 | 2025-03-20 | Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders | NANATINOSTAT, VALGANCICLOVIR | Its record names the disease | ClinicalTrials.gov |
| NCT01169636 | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | Phase 1/2 | 62 | 2021-01-06 | Hodgkin's Lymphoma | CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03057795 | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | Phase 2 | 62 | 2023-03-23 | Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | BRENTUXIMAB VEDOTIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009348/trials